To view this email in your browser, please click here.

Labline is a FREE Weekly MLO Update

September 29, 2011

In This Issue:

arrowRadiation in sync with chemotherapy cuts breast-cancer return

arrowBD launches a new generation short peripheral IV catheter to reduce risk of blood exposure to healthcare workers

arrowFar from any lab, paper bits find illness

arrowXMRV, related viruses not confirmed in blood of healthy donors or chronic fatigue syndrome patients

arrowVirus kills breast cancer cells in laboratory

arrowCSI: Microbial version without PCR

arrowHuman genetics study identifies the most common cause of ALS and dementia

arrowHot Clips: Blood Banking Tips

Programmable Temperature controlled FISH Processing System

The StatSpin Thermobrite® automates the denaturation and hybridization steps in slide-based fluorescent in situ hybridization (F)ISH assays and reduces hands-on time while ensuring precision and +/- 1º accuracy.


Radiation in sync with chemotherapy cuts breast-cancer return

Giving breast-cancer patients chemotherapy and radiation at the same time reduced the risk of tumors recurring by 35 percent, according to a U.K. study that may change the way doctors treat patients.The trial, which inv olved almost 2,300 women with early- stage breast cancer, was the largest to investigate the approach, in which radiation is administered between or during cycles of drug treatment, the researchers said today at a cancer meeting in Stockholm. Of the women who received the two treatments in this way, 41 saw their cancer return, compared with 63 of those who completed chemotherapy and then underwent radiation treatment, the researchers said.

Women participating in the study had had surgery to remove breast tumors. They then received either chemotherapy followed by radiation, or the experimental approach, known as synchronous chemoradiation. After five years, 5.1 percent of the women who had sequential courses of treatment had breast cancer return, compared with 2.8 percent of those who received synchronous chemoradiation, the study found.

More than 500 women in the study contributed to a quality- of-life analysis, which found no differences between the two approaches to treatment, the researchers said. Patients receiving synchronous therapy had worse skin reactions, though only 4 percent of them had side effects that would curb their quality of life, the study found.

arrow Visit Bloomberg for the article >>>

arrow Return to the table of contents >>>


Now Accepting Applications For Winter Enrollment

The University of Cincinnati’s NAACLS* accredited Bachelor of Science in Clinical Laboratory Science is designed for working Laboratory Technicians like you. The program is 100% online, with no required campus visits, and you can graduate in just over 2 years.

Download your free brochure today!

BD launches a new generation short peripheral IV catheter to reduce risk of blood exposure to healthcare workers

A new generation of safety short peripheral IV catheter (SPIVC) technology designed to keep healthcare workers safe from needlestick injuries and blood exposure is now available from BD Medical. In addition to proven needlestick protection, BD Insyte Autoguard BC with Blood Control Technology has also been proven to reduce the risk of blood exposure by 95 percent, compared to a non-blood control IV catheter, according to a recently published study. The new blood control technology is a septum inside of the catheter hub designed to prevent blood from leaking out during insertion.

During the insertion of SPIVCs, clinicians experience blood leakage nearly 40 percent of the time.The new BD safety catheter is designed to reduce the risk of mucocutaneous blood exposure.

arrow For more information please visit BD >>>

arrow Return to the table of contents >>>

Lab Labels That Last in Genetics

Visit us at the ASHG 12th ICHG Montreal – Booth #1018 – October 11-15, 2011 to learn more about our CryoLabels® for test tubes and plates.

Far from any lab, paper bits find illness

While other scientists successfully shrank beakers, tubes and centrifuges into diagnostic laboratories that fit into aluminum boxes that cost $50,000, George Whitesides had smaller dreams. The diagnostic tests designed in Dr. Whitesidesís Harvard University chemistry laboratory fit on a postage stamp and cost less than a penny. His secret? Paper.

His colleagues miniaturized diagnostic tests so they could move into the field with tiny pumps and thread-thin tubes. Dr. Whitesides opted for a more novel approach, reasoning that a drop of blood or urine could wick its way through a square of filter paper without any help. And if the paper could be etched with tiny channels so that the drop followed a path, and if that path were mined with dried proteins and chemically triggered dyes, the thumbnail-size square could be a mini-laboratory ó one that could be run off by the thousands on a Xerox machine.

Diagnostics for All, the private company Dr. Whitesides founded four years ago here in Bostonís Brighton neighborhood to commercialize his inspirations, has already created such a test for liver damage. It requires a single drop of blood, takes 15 minutes and can be read by an untrained eye: If a round spot the size of a sesame seed on the paper changes to pink from purple, the patient is probably in danger.

arrow Visit the New York Times for the article >>>

arrow Return to the table of contents >>>



CD4 Monitoring Solutions from BD

Get proven simplicity with the BD FACSCanto™ II flow cytometer, BD FACS™ 7-color setup beads, and BD Multitest™ reagent, the industry’s only 6-color TBNK reagent. The solution delivers consistent, reliable results and enumerates NK cells by analyzing the expression of CD16 and CD56 simultaneously in the same conjugation. Standardized analysis is delivered by BD FACSCanto™ clinical software. For a free lab assessment or to learn more, visit:

XMRV, related viruses not confirmed in blood of healthy donors or chronic fatigue syndrome patients

A study supported by the U.S. Department of Health and Human Resources examined the validity of testing techniques intended to detect the presence of several viruses, xenotropic murine leukemia virus-related virus (XMRV) or related polytropic murine leukemia viruses (P-MLVs). It could not validate or confirm previous research findings that suggested the presence of one of several viruses in blood samples of people living with chronic fatigue syndrome. The new study also could not find the viruses in blood samples of healthy donors who were previously known to not have the viruses. The new findings suggest earlier results may have resulted from laboratory error, either contamination or false positive test results.

The initial reports of a link between XMRV and chronic fatigue syndrome prompted HHS to investigate how well tests detect XMRV/P-MLVs, and the prevalence and potential transmission of these viruses in the blood supply. If the viruses had been proven to be present in patients with chronic fatigue syndrome or healthy donors, concerns were raised that these viruses could put the blood supply at risk. The new results were published online on Thursday, Sept. 22, 2011 in Science Express.

arrow Visit the NIH for the article >>>

arrow Return to the table of contents >>>

Randox Acusera Liquid Cardiac Control

The Randox Liquid Cardiac Control provides assayed target values and ranges for 10 analytes: BNP, NT-proBNP, Homocysteine, D-dimer, Myoglobin, CK-MB, Troponin I, Troponin T, Digoxin and hsCRP. It is suitable for use on many chemistry, immunoassay and POC instruments. Troponin cut off levels are in line with internationally recommended levels.

Virus kills breast cancer cells in laboratory

A nondisease-causing virus kills human breast cancer cells in the laboratory, creating opportunities for potential new cancer therapies, according to Penn State College of Medicine researchers who tested the virus on three different breast cancer types that represent the multiple stages of breast cancer development.

Adeno-associated virus type 2 (AAV2) is a virus that regularly infects humans but causes no disease. Past studies by the same researchers show that it promotes tumor cell death in cervical cancer cells infected with human papillomavirus. Researchers used an unaltered, naturally occurring version of AAV2 on human breast cancer cells.

arrow Visit PSU for the study >>>

arrow Return to the table of contents >>>

COPAN Flocked Swabs and UTM

Copan Flocked Swabs and room temperature stable Universal Transport Media (UTM) are the ideal pair for Viral Testing, improving the sensitivity of diagnostics tests. Resources on sample collection can be found at under educational videos.

CSI: Microbial version without PCR

Anyone who has watched one of the CSI: Crime Scene Investigation television shows knows that PCR (Polymerase Chain Reaction) is a technology used to amplify the tiniest samples of DNA into forensic evidence that can identify perpetrators or victims of a crime.

Microbiologists also use PCR to uncover the identity of microbes in samples taken from a wide range of sources for a wide range of purposes. However, for microbial analysis, the use of PCR technology can pose problems. Now, researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) have overcome those problems with the development of PCR-free technology that is based on Berkeley Lab's award-winning, high-density DNA-based microarray known as the PhyloChip.

"PCR amplification of microbial DNA introduces well-known distortions," says Kristen DeAngelis, lead author of the AEM paper who is now with the University of Massachusetts but remains a collaborator with the Joint BioEnergy Institute (JBEI), a DOE Bioenergy Research Center, which is led by Berkeley Lab. "For example, DNA extracted from natural environments may include DNA from microbial populations that are dead, dormant, or otherwise not directly contributing to an ecosystem's function."

arrow For more, visit Berkeley Lab >>>

arrow Return to the table of contents >>>

Human genetics study identifies the most common cause of ALS and dementia

Scientists have made an exciting breakthrough in unraveling the genetic basis of two debilitating neurodegenerative disorders, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Two independent studies, published online by Cell Press in the journal Neuron, identify a new human genetic mutation as the most common cause of ALS and FTD identified to date. This mutation explains at least a third of all familial cases of ALS and FTD within the European population. The research provides key insight into ALS and FTD and may pave the way for development of therapeutic strategies for these currently incurable diseases.

arrow Visit Science Daily for the article >>>

arrow Return to the table of contents >>>

HOT CLIPS: Blood Banking Tips - Top Picks

Click on the highlighted links below to discover last week’s top MLO archival properties concerning Blood Banking, a topic that is now at the forefront of healthcare discussions.

  1. "The give and take of blood banking", March 2010
  2. "Rare blood challenges blood bank and patients", December 2007
  3. "Automation, the workforce, and the future of the laboratory", July 2011
  4. "Blood-bank recordkeeping", April 2010

arrow Return to the table of contents >>>

Lab professionals turn to MLO for unbiased answers.

More than 41 years of excellence in peer-reviewed editorial. 

MLO - Medical
Laboratory Observer

Subscribe for Free!

The 2011 MLO
Media Handbook is online at


Subscribe to Medical Laboratory Observer | Contact the Publisher | Advertise With Us | Privacy Statement

Copyright 2011 NP Communications LLC, 2506 Tamiami Trail North, Nokomis, FL 34275